📇 Rhumatologue · MONTFERMEIL · (93) · Salarié

MME Julia ROUX

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
41 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
78.3 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 MONTFERMEIL (93)SalariéRPPS 10101095288

3 publications sur 5 ans

📊 Reconnaissance scientifique : 7/100📝 17 articles publiés🇫🇷 Publications académiques françaises (7)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2001

📚 236 citations🎯 RCR 6.59Top 5% NIH

Lire l'abstract Crossref ↓

Abstract Long-term treatment with glucocorticoids (GCs) leads to a rapid bone loss and to a greater risk of fractures. To evaluate the specific effects of this treatment on cancellous bone remodeling, structure, and microarchitecture, we compared 22 transiliac biopsy specimens taken in postmenopausal women (65 ± 6 years) receiving GCs (≥7.5 mg/day, for at least 6 months) and 22 biopsy specimens taken in age-matched women with postmenopausal osteoporosis (PMOP), all untreated and having either at least one vertebral fracture or a T score &lt; −2.5 SD. On these biopsy specimens, we measured static and dynamic parameters reflecting trabecular bone formation and resorption. Also, we performed the strut analysis and evaluated the trabecular bone pattern factor (TBPf), Euler number/tissue volume (E/TV), interconnectivity index (ICI), and marrow star volume (MaSV). Glucocorticoid-induced osteoporosis (GIOP), when compared with PMOP, was characterized by lower bone volume (BV/TV), trabecular thickness (Tb.Th), wall thickness (W.Th), osteoid thickness (O.Th), bone formation rate/bone surface (BFR/BS), adjusted mineral apposition rate/bone surface (Aj.AR/BS), and higher ICI and resorption parameters. After adjustment for BV/TV, the W.Th remained significantly lower in GIOP (p &lt; 0.0001). The active formation period [FP(a+)] was not different. Patients with GIOP were divided into two groups: high cumulative dose GCs (HGCs; 23.7 ± 9.7 g) and low cumulative dose GCs (LGCs; 2.7 ± 1.2 g). HGC when compared with LGC was characterized by lower W.Th (p &lt; 0.05), BV/TV (p &lt; 0.001), Tb.Th (p &lt; 0.05), trabecular number (Tb.N; p &lt; 0.05), FP(a+) (p &lt; 0.05), and nodes (p &lt; 0.05), and higher E/TV (p &lt; 0.05), ICI (p &lt; 0.005), and TBPf (p &lt; 0.05). When HGC was compared with PMOP, the results were similar except for the MaSV, which was significantly higher (p &lt; 0.005). In summary, GIOP was characterized by lower formation and higher resorption than in PMOP, already present after LGC. With HGCs, these changes were associated with a more dramatic bone loss caused by a major loss of trabecular connectivity.

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019

📚 132 citations🎯 RCR 7.35Top 4% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ABSTRACT Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bone formation and decreasing serum markers of bone resorption, leading to increased BMD and reduction in fracture risk in humans. We aimed to evaluate the effects of romosozumab on bone tissue. In a subset of 107 postmenopausal women with osteoporosis in the multicenter, international, randomized, double-blind, placebo-controlled Fracture Study in Postmenopausal Women with Osteoporosis (FRAME), transiliac bone biopsies were performed either after 2 (n = 34) or 12 (n = 73) months of treatment with 210 mg once monthly of romosozumab or placebo to evaluate histomorphometry and microcomputed tomography-based microarchitectural endpoints. After 2 months, compared with either baseline values assessed after a quadruple fluorochrome labeling or placebo, significant increases (P &lt; 0.05 to P &lt; 0.001) in dynamic parameters of formation (median MS/BS: romosozumab 1.51% and 5.64%; placebo 1.60% and 2.31% at baseline and month 2, respectively) were associated with a significant decrease compared with placebo in parameters of resorption in cancellous (median ES/BS: placebo 3.4%, romosozumab 1.8%; P = 0.022) and endocortical (median ES/BS: placebo 6.3%, romosozumab 1.6%; P = 0.003) bone. At 12 months, cancellous bone formation was significantly lower (P &lt; 0.05 to P &lt; 0.001) in romosozumab versus placebo and the lower values for resorption endpoints seen at month 2 persisted (P &lt; 0.001), signaling a decrease in bone turnover (P = 0.006). No significant change was observed in periosteal and endocortical bone. This resulted in an increase in bone mass and trabecular thickness with improved trabecular connectivity, without significant modification of cortical porosity at month 12. In conclusion, romosozumab produced an early and transient increase in bone formation, but a persistent decrease in bone resorption. Antiresorptive action eventually resulted in decreased bone turnover. This effect resulted in significant increases in bone mass and improved microarchitecture.© 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR).

Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice

Bone · 2015

📚 114 citations🎯 RCR 4.64Top 9% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME Julia ROUX

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (41) — classées par pathologie

Transversal28

Pédiatrie5

Corticothérapie2

Ostéoporose2

Case report / série1

Épidémiologie & registres1

Essai clinique1

Revue générale1

Vascularites1

Datasets & protocoles partagés

Partager cette fiche